|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
82,823,000 |
Market
Cap: |
2.78(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$18.92 - $34.32 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 749 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
89,268 |
111,047 |
121,047 |
489,528 |
Total Sell Value |
$2,735,873 |
$3,195,462 |
$3,439,061 |
$13,197,122 |
Total People Sold |
4 |
5 |
5 |
8 |
Total Sell Transactions |
15 |
20 |
21 |
44 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-12-06 |
4 |
AS |
$30.09 |
$295,995 |
D/D |
(9,838) |
65,275 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-12-06 |
4 |
OE |
$9.05 |
$89,034 |
D/D |
9,838 |
75,113 |
|
- |
|
Kennedy Keith |
COO / CFO |
|
2019-12-06 |
4 |
AS |
$30.04 |
$416,146 |
D/D |
(13,851) |
109,703 |
|
- |
|
Kennedy Keith |
COO / CFO |
|
2019-12-06 |
4 |
OE |
$7.47 |
$103,467 |
D/D |
13,851 |
123,554 |
|
- |
|
Jones Evan/ Fa |
Director |
|
2019-12-06 |
4 |
AS |
$30.03 |
$24,022 |
I/I |
(800) |
173,702 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-12-05 |
4 |
AS |
$30.01 |
$243,047 |
D/D |
(8,100) |
65,275 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-12-05 |
4 |
OE |
$9.05 |
$73,305 |
D/D |
8,100 |
73,375 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-12-05 |
4 |
AS |
$29.39 |
$964,142 |
D/D |
(32,803) |
46,862 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-12-05 |
4 |
OE |
$14.34 |
$470,395 |
D/D |
32,803 |
79,665 |
|
- |
|
Kennedy Keith |
COO / CFO |
|
2019-12-05 |
4 |
AS |
$30.00 |
$579,069 |
D/D |
(19,300) |
109,703 |
|
- |
|
Kennedy Keith |
COO / CFO |
|
2019-12-05 |
4 |
OE |
$5.98 |
$133,208 |
D/D |
19,300 |
129,003 |
|
- |
|
Jones Evan/ Fa |
Director |
|
2019-12-05 |
4 |
AS |
$30.00 |
$154,535 |
I/I |
(5,151) |
174,502 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-12-03 |
4 |
AS |
$26.47 |
$405,663 |
D/D |
(15,327) |
46,862 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-12-03 |
4 |
OE |
$5.43 |
$107,103 |
D/D |
15,032 |
62,189 |
|
- |
|
Anderson Bonnie H |
Chairman and CEO |
|
2019-12-02 |
4 |
D |
$27.19 |
$26,864 |
D/D |
(988) |
102,738 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-12-02 |
4 |
D |
$27.19 |
$5,900 |
D/D |
(217) |
65,275 |
|
- |
|
Kennedy Keith |
COO / CFO |
|
2019-12-02 |
4 |
D |
$27.19 |
$9,245 |
D/D |
(340) |
109,703 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-12-02 |
4 |
D |
$27.19 |
$7,939 |
D/D |
(292) |
47,157 |
|
- |
|
Ho Mark |
Principal Accounting Officer |
|
2019-12-02 |
4 |
D |
$27.19 |
$1,767 |
D/D |
(65) |
21,758 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-11-27 |
4 |
AS |
$29.36 |
$108,534 |
D/D |
(3,697) |
47,449 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-11-27 |
4 |
OE |
$14.34 |
$53,015 |
D/D |
3,697 |
51,146 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-11-18 |
4 |
AS |
$25.18 |
$492,788 |
D/D |
(19,571) |
65,492 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-11-18 |
4 |
OE |
$6.45 |
$126,233 |
D/D |
19,571 |
85,063 |
|
- |
|
Anderson Bonnie H |
Chairman and CEO |
|
2019-11-15 |
4 |
AS |
$25.06 |
$501,124 |
D/D |
(20,000) |
103,726 |
|
- |
|
Anderson Bonnie H |
Chairman and CEO |
|
2019-11-15 |
4 |
OE |
$4.00 |
$80,000 |
D/D |
20,000 |
123,726 |
|
- |
|
582 Records found
|
|
Page 15 of 24 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|